Solid Biosciences Inc
SLDBHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:45 AM ET
6.91-0.09 (-1.29%)
2026-11-13 14:06 CET
Market cap
$771.23M
Revenue, TTM
0.00 USD m
Net income, TTM
-215.27 USD m
Free cash flow, TTM
-200.30 USD m
EPS diluted, TTM
-1.78
Price
SLDB against its 20, 50 and 200-day averagesPatternshover a marker to name it
39.7% under the 52-week high of 11.45 on 6 Jul 2026. 52-week low 4.16 on 14 Nov 2025. Last 15 sessions, 36.8% high to low
Volume 0.01× normal · the line is the 50-bar volume average
Setup. RS line 42
CANSLIM 4 of 6 — fails: EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Zanger 1 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 2 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 1 of 4 — fails: EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Accumulation 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
SLDB52-week range, 38% of the way up
4.1611.45
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
| Index | RUT |
|---|---|
| Employees | 121 |
| IPO | Jan 26, 2018 |
| Beta | 2.62 |
| ATR, 14d | 0.52 |
| Rel volume | 0.01 |
| Short float | 14.61% |
| Insider own | 18.41% |
| Inst own | 87.52% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $771.23M |
| Enterprise Value | 441.28M |
| Income | -215.27M |
| Sales | 0.00M |
| Book / share | 3.07 |
| Cash / share | 3.13 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 121 |
| IPO | Jan 26, 2018 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 2.25 |
| Price / cash | 2.21 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 11.99 |
| Current Ratio | 11.99 |
| Debt / equity | 0.06 |
| Long-term debt / equity | 0.05 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -1.78 |
|---|---|
| Earnings next year | -1.58 |
| Earnings next quarter | -0.39 |
| Earnings this year | 16.71% |
| Earnings next year | 4.54% |
| Earnings growth, 5 years | 19.20% |
| Past earnings growth | 41.79% 39.94% |
| Past sales growth | - - |
| Earnings vs last year | 28.59% |
| Sales vs last year | - |
| Earnings vs last quarter | 26.32% |
| Sales vs last quarter | - |
| Earnings | Nov 04 AMC |
| Surprise | 12.04% - |
Ownership
| Insiders own | 18.41% |
|---|---|
| Insider trades | -0.02% |
| Institutions own | 87.52% |
| Institution trades | 11.54% |
| Return on assets | -64.86% |
| Return on equity | -76.87% |
| Return on capital | -59.89% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | 6.98% |
| 50-day average | -3.98% |
| 200-day average | -10.07% |
Technical
| Shares out | 111.56M |
|---|---|
| Shares floating | 91.06M |
| Short / float | 14.61% |
| Short ratio | 10.62 |
| Short interest | 13.30M |
| 52-week high | 11.45 -39.7% |
| 52-week low | 4.16 +66.3% |
| Volatility | 8.83% 7.81% |
| Average range | 0.52 |
| Strength index | 52.15 |
| Market sensitivity | 2.62 |
| Relative volume | 0.01 |
| Avg Volume | 1.25M |
| Volume | 626 |
Performance
| Perf Week | 4.86% |
|---|---|
| Perf Month | 20.38% |
| Perf Quarter | -24.07% |
| Perf Half Y | -0.14% |
| Perf YTD | 22.52% |
| Perf Year | 60.70% |
| Perf 3Y | 219.91% |
| Perf 5Y | -78.57% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 18.71 |
| Prev Close | 7.00 |
| Price | 6.91 |
| Change % | -1.29% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Nov 09, 2026 | Resumed | William Blair | Outperform | ||
| Oct 15, 2026 | Initiated | UBS | Buy | $20 | +189.4% |
| Sep 16, 2026 | Initiated | RBC Capital Mkts | Outperform | $18 | +160.5% |
| Aug 21, 2026 | Resumed | Truist | Buy | $20 | +189.4% |
| Mar 20, 2026 | Initiated | Guggenheim | Buy | $26 | +276.3% |
| Dec 04, 2025 | Initiated | Needham | Buy | $16 | +131.5% |
| Jun 26, 2025 | Initiated | Citigroup | Buy | $14 | +102.6% |
| Jan 08, 2025 | Initiated | Truist | Buy | $16 | +131.5% |
| Dec 13, 2024 | Initiated | Wedbush | Outperform | $16 | +131.5% |
| Dec 10, 2024 | Initiated | JMP Securities | Mkt Outperform | $15 | +117.1% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| SRPT | Sarepta Therapeutics Inc | 1.74B |
| RGNX | Regenxbio Inc | 560.71M |
| DYN | Dyne Therapeutics Inc | 3.19B |
| WVE | Wave Life Sciences Inc | 639.02M |
| CAPR | Capricor Therapeutics Inc | 590.73M |
| LXEO | Lexeo Therapeutics Inc | 238.88M |
| EWTX | Edgewise Therapeutics Inc | 5.00B |
| RCKT | Rocket Pharmaceuticals Inc | 259.07M |
| TRDA | Entrada Therapeutics Inc | 202.41M |
| PTCT | PTC Therapeutics Inc | 5.27B |
Insider trading
latest 14 of 49| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Brooks Gabriel | Chief Medical Officer | Oct 19 '26 | Sale | 5.62 | 4,374 | 24,582 | 97,241 | Oct 20 04:05 PM |
| Cumbo Alexander | President and CEO | Feb 18 '26 | Sale | 5.82 | 16,644 | 96,923 | 235,405 | Feb 18 09:38 PM |
| Brooks Gabriel | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 5,563 | 32,395 | Feb 18 09:35 PM | |
| Cumbo Alexander | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 16,644 | 96,923 | Feb 18 09:35 PM | |
| Hanrahan Jessie | Chief Regulatory Officer | Feb 18 '26 | Sale | 5.82 | 4,134 | 24,074 | 74,318 | Feb 18 09:34 PM |
| Hanrahan Jessie | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 4,134 | 24,074 | Feb 18 09:33 PM | |
| Ganot Ilan | Director | Feb 18 '26 | Sale | 5.82 | 2,658 | 15,478 | 27,474 | Feb 18 09:32 PM |
| Herzich Paul | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 3,616 | 21,057 | Feb 18 09:32 PM | |
| Ganot Ilan | Director | Feb 18 '26 | Proposed Sale | 5.92 | 2,658 | 15,748 | Feb 18 09:31 PM | |
| Herzich Paul | Chief Technology Officer | Feb 18 '26 | Sale | 5.82 | 3,616 | 21,057 | 72,638 | Feb 18 09:31 PM |
| Howton David T | Chief Operating Officer | Feb 18 '26 | Sale | 5.82 | 7,469 | 43,494 | 105,077 | Feb 18 09:31 PM |
| Howton David T | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 7,469 | 43,494 | Feb 18 09:30 PM | |
| Tan Kevin | Officer | Feb 18 '26 | Proposed Sale | 5.82 | 5,404 | 31,469 | Feb 18 09:28 PM | |
| Tan Kevin | CFO & Treasurer | Feb 18 '26 | Sale | 5.82 | 5,404 | 31,469 | 99,422 | Feb 18 09:25 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
News
latest 14 of 200- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
- Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference (GlobeNewswire) -5.21%
- Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
- Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich's Ataxia (GlobeNewswire)
- Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026 (GlobeNewswire) +8.11%
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
- Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
- BioGene Therapeutics Inc. Appoints Ty Howton to Board of Directors (TMX Newsfile)
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
- Solid Biosciences to Participate at Upcoming Investor Conferences (GlobeNewswire)
- Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
- Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy (GlobeNewswire)
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Quarterly earnings
2026Q3 EPS -0.360 beat -0.409, from -0.480 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-04 16:30 | -0.360 | -0.409 | -0.359 | 0.00 | 0.00 | EPS -12.0% · sales - | vs 2025Q3, year-ago quarter · EPS -25.0% · sales - | 14 EPS · 8 sales | Open +1.23% vs SPY -0.17%. Close -5.21% vs SPY -4.41% |
| 2026Q2ended 2026-06-30 | 2026-08-06 16:30 | -0.380 | -0.462 | -0.381 | 0.00 | 0.00 | EPS -17.8% · sales - | vs 2025Q2, year-ago quarter · EPS -9.5% · sales - | 12 EPS · 9 sales | Open -2.07% vs SPY +0.32%. Close -3.67% vs SPY +0.61% |
| 2026Q1ended 2026-03-31 | 2026-05-12 16:30 | -0.520 | -0.429 | -0.517 | 0.00 | 0.00 | EPS +21.3% · sales - | vs 2025Q1, year-ago quarter · EPS -11.9% · sales - | 13 EPS · 9 sales | Open -2.85% vs SPY +0.04%. Close -4.40% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-19 16:30 | -0.530 | -0.519 | -0.526 | 0.00 | 0.00 | EPS +2.2% · sales - | vs 2024Q4, year-ago quarter · EPS -47.0% · sales - | 13 EPS · 9 sales | Open +4.78% vs SPY -0.50%. Close -1.26% vs SPY -1.70% |
| 2025Q3ended 2025-09-30 | 2025-11-03 16:30 | -0.480 | -0.439 | -0.485 | 0.00 | 0.00 | EPS +9.3% · sales - | vs 2024Q3, year-ago quarter · EPS -39.2% · sales - | 13 EPS · 9 sales | Open -9.42% vs SPY -1.06%. Close -15.29% vs SPY -1.19% |
| 2025Q2ended 2025-06-30 | 2025-08-12 16:30 | -0.420 | -0.497 | -0.419 | 0.00 | 0.00 | EPS -15.4% · sales - | vs 2024Q2, year-ago quarter · EPS -31.1% · sales - | 13 EPS · 10 sales | Open 0.00% vs SPY +0.35%. Close +10.60% vs SPY +0.34% |
| 2025Q1ended 2025-03-31 | 2025-05-15 16:30 | -0.590 | -0.555 | -0.592 | 0.00 | 0.00 | EPS +6.3% · sales - | vs 2024Q1, year-ago quarter · EPS -7.8% · sales - | 12 EPS · 8 sales | Open +11.58% vs SPY +0.13%. Close +6.95% vs SPY +0.63% |
| 2024Q4ended 2024-12-31 | 2025-03-06 16:30 | -1.000 | -0.805 | -0.997 | 0.00 | 0.00 | EPS +24.2% · sales - | vs 2023Q4, year-ago quarter · EPS +0.2% · sales - | 12 EPS · 8 sales | Open -4.55% vs SPY -0.32%. Close -1.45% vs SPY +0.56% |
| 2024Q3ended 2024-09-30 | 2024-11-06 16:30 | -0.790 | -0.668 | -0.790 | 0.00 | 0.00 | EPS +18.2% · sales - | vs 2023Q3, year-ago quarter · EPS -24.8% · sales - | 9 EPS · 7 sales | Open -0.65% vs SPY +0.35%. Close -6.03% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-13 16:30 | -0.610 | -0.664 | -0.613 | 0.00 | 0.00 | EPS -8.1% · sales - | vs 2023Q2, year-ago quarter · EPS -51.2% · sales - | 8 EPS · 6 sales | Open +3.57% vs SPY +0.15%. Close +14.54% vs SPY +0.32% |
| 2024Q1ended 2024-03-31 | 2024-05-09 12:00 | -0.640 | -0.640 | -0.637 | 0.00 | 1.45 | EPS +0.0% · sales -100.0% | vs 2023Q1, year-ago quarter · EPS -58.5% · sales - | 8 EPS · 5 sales | Open +0.68% vs SPY +0.04%. Close +0.88% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-03-13 08:30 | -0.998 | -1.023 | -0.998 | 0.00 | 0.00 | EPS -2.5% · sales - | vs 2022Q4, year-ago quarter · EPS +26.3% · sales - | 5 EPS · 3 sales | Open -6.32% vs SPY +0.06%. Close +7.28% vs SPY -0.16% |
| 2023Q3ended 2023-09-30 | 2023-11-08 16:30 | -1.050 | -1.182 | -1.046 | 0.00 | 0.00 | EPS -11.2% · sales - | vs 2022Q3, year-ago quarter · EPS -61.3% · sales -100.0% | 5 EPS · 3 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-14 16:30 | -1.251 | -1.370 | -1.253 | 0.00 | 2.20 | EPS -8.7% · sales -100.0% | vs 2022Q2, year-ago quarter · EPS -62.1% · sales -100.0% | 4 EPS · 2 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-16 16:30 | -1.540 | -1.612 | -1.537 | 0.00 | 2.20 | EPS -4.4% · sales -100.0% | vs 2022Q1, year-ago quarter · EPS -53.3% · sales -100.0% | 4 EPS · 2 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-23 08:30 | -0.790 | -1.505 | -0.775 | 0.00 | 0.00 | EPS -47.5% · sales - | vs 2021Q4, year-ago quarter · EPS -67.1% · sales -100.0% | 3 EPS · 2 sales | - |
Annual earnings
2025FY EPS -1.990 beat -2.116, from -3.060 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.976 | - | - | 582.26 | 7.08 |
| 2029FYestimate | - | -0.186 | - | - | 301.86 | - |
| 2028FYestimate | - | -1.050 | - | - | 105.46 | - |
| 2027FYestimate | - | -1.582 | - | - | 10.31 | - |
| 2026FYestimate | - | -1.658 | - | - | 0.00 | - |
| 2025FY | -1.990 | -2.116 | -1.990 | 0.00 | 0.00 | - |
| 2024FY | -3.060 | -2.937 | -3.055 | 0.00 | 0.00 | - |
| 2023FY | -4.830 | -4.762 | -4.829 | 0.00 | 0.00 | - |
| 2022FY | -10.100 | -6.829 | -10.101 | 8.09 | 8.10 | - |
| 2021FY | -10.200 | -10.770 | -10.142 | 13.69 | 12.10 | - |
| 2020FY | -25.500 | -25.500 | -25.499 | 0.00 | 0.00 | - |
| 2019FY | -43.650 | -41.850 | -43.643 | 0.00 | 0.00 | - |
| 2018FY | -33.750 | -33.131 | -33.731 | 0.00 | 0.00 | - |
| 2017FY | -43.200 | -34.920 | -17.269 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -1.66 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-11 | -1.66 | -0.2% |
| 2026Q4 | E | per share | 2026-11-11 | -0.39 | -0.5% |
| 2026FY | R | per share | 2026-11-11 | -1.59 | -0.5% |
| 2026Q4 | R | per share | 2026-11-11 | -0.37 | -1.2% |
| 2026Q4 | S | per share | 2026-11-05 | 0.00 | - |
| 2026Q3 | E | per share | 2026-10-24 | -0.41 | 0.0% |
| 2026Q3 | R | per share | 2026-10-24 | -0.40 | 0.0% |
| 2026FY | S | per share | 2026-10-13 | 0.00 | - |
| 2026Q3 | S | per share | 2026-09-22 | 0.00 | - |
| 2026Q2 | E | per share | 2026-08-01 | -0.46 | 0.0% |
| 2026Q2 | R | per share | 2026-08-01 | -0.49 | 0.0% |
| 2026Q2 | S | per share | 2026-07-30 | 0.00 | - |
| 2026Q1 | E | per share | 2026-05-06 | -0.43 | +0.0% |
| 2026Q1 | R | per share | 2026-03-24 | -0.40 | +2.3% |
| 2026Q1 | S | per share | 2026-03-20 | 0.00 | - |
| 2025FY | E | per share | 2026-03-18 | -2.03 | -2.9% |
| 2025Q4 | E | per share | 2026-03-18 | -0.51 | -1.2% |
| 2025FY | R | per share | 2026-03-18 | -2.00 | +0.8% |
| 2025Q4 | R | per share | 2026-03-18 | -0.52 | +2.0% |
| 2025FY | S | per share | 2026-03-18 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-18 | 0.00 | - |
| 2025Q3 | S | per share | 2025-11-01 | 0.00 | - |
| 2025Q3 | E | per share | 2025-10-27 | -0.43 | 0.0% |
| 2025Q3 | R | per share | 2025-10-27 | -0.42 | 0.0% |
| 2025Q2 | E | per share | 2025-08-04 | -0.50 | 0.0% |
| 2025Q2 | R | per share | 2025-08-04 | -0.54 | 0.0% |
| 2025Q2 | S | per share | 2025-06-26 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-29 | -0.56 | 0.0% |
| 2025Q1 | R | per share | 2025-04-17 | -0.51 | +2.5% |
| 2025Q1 | S | per share | 2025-03-07 | 0.00 | - |
| 2024FY | E | per share | 2025-02-18 | -2.94 | 0.0% |
| 2024Q4 | E | per share | 2025-02-18 | -0.80 | 0.0% |
| 2024FY | R | per share | 2025-01-25 | -3.00 | 0.0% |
| 2024Q4 | R | per share | 2025-01-25 | -0.79 | 0.0% |
| 2024FY | S | per share | 2025-01-15 | 0.00 | - |
| 2024Q4 | S | per share | 2025-01-15 | 0.00 | - |
| 2024Q3 | E | per share | 2024-11-04 | -0.67 | 0.0% |
| 2024Q3 | R | per share | 2024-10-28 | -0.66 | 0.0% |
| 2024Q3 | S | per share | 2024-09-25 | 0.00 | - |
| 2024Q2 | E | per share | 2024-08-13 | -0.65 | 0.0% |
| 2024Q2 | R | per share | 2024-08-13 | -0.66 | 0.0% |
| 2024Q2 | S | per share | 2024-08-07 | 0.40 | -14.3% |
| 2024Q1 | E | per share | 2024-03-28 | -0.64 | -2.4% |
| 2024Q1 | R | per share | 2024-03-28 | -0.54 | -1.2% |
| 2024Q1 | S | per share | 2024-03-27 | 1.45 | -20.0% |
| 2023FY | E | per share | 2024-02-16 | -4.76 | -0.1% |
| 2023FY | R | per share | 2024-02-16 | -4.55 | -1.3% |
| 2023FY | S | per share | 2024-02-16 | 0.00 | -100.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -17.269 | -33.731 | -43.643 | -25.499 | -10.142 | -10.101 | -4.829 | -3.055 | -1.992 | -1.7808 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 14 | 8 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 2 | 2 | 3 | 6 | 7 | 20 | 20 | 40 | 79 | - | 112 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.79 | -0.997 | -0.592 | -0.419 | -0.485 | -0.526 | -0.517 | -0.381 | -0.357 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 39 | 40 | 77 | 78 | 78 | 79 | 98 | 105 | 112 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 8.09-40.6% | 13.62 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 1.67 | 1.64-33.3% | 2.46-4.7% | 2.58+7.1% | 2.41-18.6% | 2.96-24.5% | 3.92+39.0% | 2.82+79.6% | 1.57 |
| Gross Profit | -1.67 | -1.64 | -2.46 | -2.58-145.3% | 5.69-46.6% | 10.66 | -3.92 | -2.82 | -1.57 |
| Selling, General and Administrative Excl. Other | 220.08 | 177.57+39.5% | 127.27+25.1% | 101.73+1.6% | 100.09+20.7% | 82.91+0.4% | 82.54-29.1% | 116.49+57.2% | 74.12 |
| Research and Development | 172.13 | 140.32+45.5% | 96.43+26.0% | 76.56-2.4% | 78.42+33.5% | 58.74-9.5% | 64.88-31.5% | 94.74+63.4% | 57.97 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -221.75 | -179.21 | -129.73 | -104.31 | -94.40 | -72.25 | -86.46 | -119.32 | -75.69 |
| Interest Expense | 0.00 | 0.00-100.0% | 0.34 | - | - | - | - | - | - |
| Unusual Expense | 5.00 | 6.05+27.4% | 4.75 | -0.06-100.5% | 12.05 | 0.00-100.0% | 1.94 | 0.00 | 0.00 |
| Net Income Before Taxes | -215.27 | -174.32 | -124.70 | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 | -74.80 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -215.27 | -174.32 | -124.70 | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 | -74.80 |
| Net Income From Continuing Operations | -215.27 | -174.32 | -124.70 | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 | -74.80 |
| Net Income | -215.27 | -174.32 | -124.70 | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 | -74.80 |
| EPS (Recurring) per share | -1.40 | -1.94 | -2.97 | -4.83 | -9.11 | -10.14 | -25.11 | -43.64 | -33.73 |
| EPS (Basic, Before Extraordinaries) per share | -1.78 | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | -43.64 | -33.73 |
| EPS (Diluted) per share | -1.78 | -1.99 | -3.06 | -4.83 | -10.10 | -10.14 | -25.50 | -43.64 | -33.73 |
| EBITDA | -220.08 | -177.57 | -127.27 | -101.73 | -92.00 | -69.29 | -82.54 | -116.49 | -74.12 |
| Non-Operating Income (Expense) | 11.48 | 10.93+8.0% | 10.12+22.8% | 8.24-59.7% | 20.47+29142.9% | 0.07-41.7% | 0.12-94.3% | 2.10+136.0% | 0.89 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 23.41 | 16.91+60.7% | 10.52+38.1% | 7.62+1.1% | 7.54-43.6% | 13.37+15.0% | 11.63-18.2% | 14.21+138.4% | 5.96 |
| Price To Sales Ratio ratio | - | - | - | - | 5.66 | 13.72 | - | - | - |
| Gross Margin % | - | - | - | - | 70.25 | 78.24 | - | - | - |
| Operating Margin % | - | - | - | - | -1,166.35 | -530.50 | - | - | - |
| Net Margin % | - | - | - | - | -1,062.28 | -530.01 | - | - | - |
| Shares Outstanding million shares | 111.56 | 78.97+95.1% | 40.47+98.5% | 20.39+4.2% | 19.56+165.8% | 7.36+30.0% | 5.66+84.4% | 3.07+30.1% | 2.36 |
| Market Capitalization | 781.28 | 781.28+388.8% | 159.82+29.0% | 123.89+17.9% | 105.06-45.6% | 193.10-70.0% | 643.50+214.5% | 204.64-78.4% | 949.59 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.42+10.5% | 0.390.0% | 0.40-2.4% | 0.47-4.1% | 0.38-7.3% | 0.39-68.5% | 0.41+24.2% | 0.49-16.9% |
| Gross Profit | -0.42 | -0.39 | -0.40 | -0.47 | -0.38 | -0.39 | -0.41 | -0.49 |
| Selling, General and Administrative Excl. Other | 57.24+20.1% | 56.99+38.0% | 56.91+43.5% | 48.94+24.2% | 47.68+37.1% | 41.31+55.6% | 39.65+49.4% | 39.41+81.8% |
| Research and Development | 43.59+12.2% | 44.27+36.6% | 46.14+49.3% | 38.13+23.9% | 38.86+42.2% | 32.41+66.5% | 30.91+63.8% | 30.77+99.2% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -57.66 | -57.38 | -57.31 | -49.40 | -48.06 | -41.69 | -40.05 | -39.90 |
| Interest Expense | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | - | 0.06-33.3% | 0.07-30.0% | 0.07 |
| Unusual Expense | -0.15-117.6% | 0.85-5.6% | 1.650.0% | 2.65-44.2% | 0.85 | 0.90 | 1.65 | 4.75 |
| Net Income Before Taxes | -53.95 | -54.80 | -56.74 | -49.79 | -45.78 | -39.48 | -39.28 | -42.60 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -53.95 | -54.80 | -56.74 | -49.79 | -45.78 | -39.48 | -39.28 | -42.60 |
| Net Income From Continuing Operations | -53.95 | -54.80 | -56.74 | -49.79 | -45.78 | -39.48 | -39.28 | -42.60 |
| Net Income | -53.95 | -54.80 | -56.74 | -49.79 | -45.78 | -39.48 | -39.28 | -42.60 |
| EPS (Recurring) per share | -0.36 | -0.38 | -0.51 | -0.51 | -0.48 | -0.41 | -0.57 | -0.92 |
| EPS (Basic, Before Extraordinaries) per share | -0.36 | -0.38 | -0.52 | -0.53 | -0.48 | -0.42 | -0.59 | -1.00 |
| EPS (Diluted) per share | -0.36 | -0.38 | -0.52 | -0.53 | -0.48 | -0.42 | -0.59 | -1.00 |
| EBITDA | -57.24 | -56.99 | -56.91 | -48.94 | -47.68 | -41.31 | -39.65 | -39.41 |
| Non-Operating Income (Expense) | 3.56+13.7% | 3.44+8.5% | 2.22-10.8% | 2.27+7.1% | 3.13+23.2% | 3.17+13.2% | 2.49-6.0% | 2.12+36.8% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 6.15+56.5% | 5.62+78.4% | 5.15+54.2% | 6.50+70.2% | 3.93+31.0% | 3.15+50.7% | 3.34+107.5% | 3.82+96.9% |
| Shares Outstanding million shares | 111.56+43.2% | 105.13+35.5% | 98.39+27.0% | 78.97+95.1% | 77.88+100.1% | 77.60+101.3% | 77.49+104.8% | 40.47+98.5% |
| Market Capitalization | 781.28+62.6% | 983.51+160.5% | 708.42+147.1% | 439.41+174.9% | 480.45+78.6% | 377.50+73.5% | 286.72-43.0% | 159.82+29.0% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 189.07+27.0% | 148.92+20.4% | 123.64-42.1% | 213.72+2.9% | 207.78+34.3% | 154.74+85.3% | 83.52-31.8% | 122.46+77.2% | 69.09 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 16.38+95.5% | 8.38+37.6% | 6.09+2.9% | 5.92-59.8% | 14.72+253.8% | 4.16+49.6% | 2.78-54.9% | 6.17+295.5% | 1.56 |
| Total Current Assets | 205.46+30.6% | 157.30+21.3% | 129.73-40.9% | 219.64-1.3% | 222.61+40.1% | 158.90+84.1% | 86.30-32.9% | 128.64+82.1% | 70.66 |
| Net Property, Plant & Equipment | 26.09-10.2% | 29.04-12.4% | 33.16-14.1% | 38.61+408.0% | 7.60-35.2% | 11.73-29.5% | 16.63+59.6% | 10.42+328.8% | 2.43 |
| Total Investments and Advances | 0.77-60.5% | 1.95+6.6% | 1.830.0% | 1.83-11.6% | 2.07+527.3% | 0.330.0% | 0.33 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | - | - | - | - | 0.00 | 0.00 |
| Other Assets | 0.22-40.5% | 0.37+76.2% | 0.21+23.5% | 0.17+88.9% | 0.09-57.1% | 0.210.0% | 0.21-61.1% | 0.54-82.6% | 3.11 |
| Total Assets | 232.54+23.3% | 188.66+14.4% | 164.94-36.6% | 260.25+12.0% | 232.38+35.8% | 171.17+65.4% | 103.47-25.9% | 139.60+83.2% | 76.19 |
| Short Term Debt Incl. Current Port. of LT Debt | 2.10-30.5% | 3.02+30.2% | 2.32-9.4% | 2.56+70.7% | 1.50-32.1% | 2.21+15.1% | 1.92+1029.4% | 0.17 | 0.00 |
| Accounts Payable | 3.22-24.1% | 4.24+108.9% | 2.03-37.3% | 3.24-27.4% | 4.46+36.4% | 3.27-54.1% | 7.12+93.0% | 3.69-27.2% | 5.07 |
| Other Current Liabilities | 28.14+22.3% | 23.00+126.4% | 10.16-39.2% | 16.70-5.3% | 17.64-7.2% | 19.00+105.9% | 9.23+7.1% | 8.62+38.8% | 6.21 |
| Total Current Liabilities | 33.47+10.6% | 30.26+108.4% | 14.52-35.5% | 22.51-4.6% | 23.60-3.6% | 24.48+33.9% | 18.28+46.5% | 12.48+10.7% | 11.27 |
| Long Term Debt | 19.06-9.9% | 21.16-11.6% | 23.94-7.9% | 25.98+4457.9% | 0.57-80.6% | 2.94-42.9% | 5.15+498.8% | 0.86 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00-100.0% | 0.10 | 0.00-100.0% | 11.66 | 0.00-100.0% | 1.07 | 0.00 |
| Total Liabilities | 52.53+2.2% | 51.42+33.7% | 38.46-20.8% | 48.59+101.0% | 24.17-38.2% | 39.08+66.9% | 23.42+62.5% | 14.41+27.9% | 11.27 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 124.18 |
| Common Equity | 180.01+31.2% | 137.25+8.5% | 126.48-40.2% | 211.67+1.7% | 208.21+57.6% | 132.09+65.0% | 80.05-36.1% | 125.18 | -59.26 |
| Total Shareholders Equity | 180.01+31.2% | 137.25+8.5% | 126.48-40.2% | 211.67+1.7% | 208.21+57.6% | 132.09+65.0% | 80.05-36.1% | 125.18+92.8% | 64.92 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 180.01+31.2% | 137.25+8.5% | 126.48-40.2% | 211.67+1.7% | 208.21+57.6% | 132.09+65.0% | 80.05-36.1% | 125.18+92.8% | 64.92 |
| Total Liabilities & Stockholders Equity | 232.54+23.3% | 188.66+14.4% | 164.94-36.6% | 260.25+12.0% | 232.38+35.8% | 171.17+65.4% | 103.47-25.9% | 139.60+83.2% | 76.19 |
| Book Value Per Share per share | 2.28-32.7% | 3.39-45.3% | 6.20-42.7% | 10.82-61.8% | 28.30+21.3% | 23.34-10.6% | 26.11-50.7% | 53.00 | -26.03 |
| Tangible Book Value Per Share per share | 2.28-32.7% | 3.39-45.3% | 6.20-42.7% | 10.82-61.8% | 28.30+21.3% | 23.34-10.6% | 26.11-50.7% | 53.00 | -26.03 |
| Full-Time Employees people | 121+21.0% | 100+13.6% | 88+1.1% | 87-16.3% | 104+48.6% | 70-42.1% | 121+9.0% | 111+85.0% | 60 |
| Price to Book Ratio ratio | 2.28 | 0.93 | 0.85 | 0.28 | 0.93 | 4.87 | 2.56 | 7.59 | 6.35 |
| Return on Assets % | -82.78 | -70.53 | -45.16 | -34.91 | -35.78 | -64.30 | -96.45 | -69.32 | -92.52 |
| Return on Equity % | -109.90 | -94.57 | -56.79 | -40.96 | -42.43 | -83.24 | -114.24 | -78.69 | -207.02 |
| Return on Invested Capital % | -87.57 | -78.72 | -63.83 | -36.18 | -34.58 | -65.39 | -137.59 | -59.34 | -83.24 |
| Quick Ratio ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 |
| Current Ratio ratio | 6.14 | 5.20 | 8.94 | 9.76 | 9.43 | 6.49 | 4.72 | 10.31 | 6.27 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -215.27 | -174.32 | -124.70 | -96.02 | -85.98 | -72.19 | -88.29 | -117.22 | -74.80 |
| Depreciation | 1.67 | 1.64-33.3% | 2.46-4.7% | 2.58+7.1% | 2.41-18.6% | 2.96-24.5% | 3.92+39.0% | 2.82+79.6% | 1.57 |
| Other Funds (Non Cash) | 26.74 | 23.22+19.8% | 19.38+246.7% | 5.59 | -10.71-173.9% | 14.50+24.9% | 11.61-16.7% | 13.93+137.3% | 5.87 |
| Funds from Operations | -186.86 | -149.47 | -102.86 | -87.84 | -94.29 | -54.72 | -72.76 | -100.47 | -67.36 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -12.06 | -6.82-339.3% | 2.85 | -6.34 | -3.69 | -23.04-242.6% | 16.16+108.5% | 7.75 | -2.83 |
| Cash from Operating Activities | -198.92 | -156.29 | -100.01 | -94.18 | -97.98 | -77.76 | -56.60 | -92.71 | -70.20 |
| Capital Expenditures | -1.38 | -1.15 | -0.65 | -1.51 | -3.02 | -1.28 | -0.90 | -4.39 | -7.78 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.09 | 0.09+800.0% | 0.01 | 0.00-100.0% | 32.12 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -44.20 | -57.39 | -15.44-237.9% | 11.20-62.7% | 30.05 | -89.81-1297.5% | 7.50-74.0% | 28.90 | -18.99 |
| Purchase of Investments | -351.98 | -235.89 | -204.34 | -117.43 | -182.76 | -141.25 | -0.40 | -31.50 | -44.32 |
| Sale Or Maturity of Investments | 307.78 | 178.50-5.5% | 188.90+46.9% | 128.63-39.6% | 212.81+313.7% | 51.44+551.1% | 7.90-86.9% | 60.40+138.4% | 25.34 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | -0.09 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -45.58 | -58.45 | -16.09-266.0% | 9.69-83.6% | 59.16 | -91.09-1480.2% | 6.60-73.1% | 24.52 | -26.76 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 308.21 | 194.74+58.9% | 122.57+4026.9% | 2.97-95.9% | 72.57-46.2% | 134.92+4.8% | 128.70+114.6% | 59.98-55.1% | 133.69 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 308.21 | 194.74+58.9% | 122.57+4026.9% | 2.97-95.9% | 72.57-46.2% | 134.92+4.8% | 128.70+114.6% | 59.98-55.1% | 133.69 |
| Proceedsfrom Stock Options | 497.82 | 194.74+1368.6% | 13.26+346.5% | 2.97-95.9% | 72.55-46.2% | 134.88+4.8% | 128.70+114.6% | 59.98-55.1% | 133.69 |
| Issuance or Reduction of Debt, Net | -0.20 | -0.72 | -0.47 | 0.00-100.0% | 2.08 | 0.00 | 0.00 | 0.00 | -0.01 |
| Change in Long Term Debt | -0.20 | -0.72 | -0.47 | 0.00-100.0% | 2.08 | 0.00 | 0.00 | 0.00 | -0.01 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 2.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -0.20 | -0.72 | -0.47 | 0.00 | -0.07 | 0.00 | 0.00 | 0.00 | -0.01 |
| Net Financing Active Other Cash Flow | 0.52 | 0.42+23.5% | 0.34+126.7% | 0.15-16.7% | 0.18+157.1% | 0.07 | 0.00 | -2.10 | -2.17 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.10 | -2.17 |
| Cash from Financing Activities | 308.53 | 194.45+58.8% | 122.44+3824.4% | 3.12-95.8% | 74.83-44.6% | 134.99+4.9% | 128.70+122.4% | 57.88-56.0% | 131.51 |
| Net Change in Cash | 64.03 | -20.30-420.2% | 6.34 | -81.37-326.0% | 36.01 | -33.87-143.0% | 78.70 | -10.32-129.9% | 34.55 |
| Free Cash Flow | -200.30 | -157.44 | -100.67 | -95.69 | -100.99 | -79.05 | -57.50 | -97.10 | -77.97 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 349.57+48.0% | 378.32+41.1% | 381.32+24.2% | 189.07+27.0% | 236.14+38.0% | 268.11+40.9% | 306.92+48.9% | 148.92+20.4% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 15.63+79.4% | 16.79+59.4% | 15.47+138.4% | 16.38+95.5% | 8.71+3.9% | 10.53+43.5% | 6.49-20.2% | 8.38+37.6% |
| Total Current Assets | 365.19+49.1% | 395.11+41.8% | 396.79+26.6% | 205.46+30.6% | 244.85+36.4% | 278.64+41.0% | 313.41+46.3% | 157.30+21.3% |
| Net Property, Plant & Equipment | 23.75-11.7% | 24.63-10.3% | 25.21-10.6% | 26.09-10.2% | 26.89-10.2% | 27.45-11.3% | 28.20-13.2% | 29.04-12.4% |
| Total Investments and Advances | 0.71-63.0% | 0.71-63.0% | 0.71-64.0% | 0.77-60.5% | 1.92-0.5% | 1.92+0.5% | 1.97+7.7% | 1.95+6.6% |
| Other Assets | 0.250.0% | 0.14-50.0% | 0.18-43.8% | 0.22-40.5% | 0.25-46.8% | 0.28-46.2% | 0.32+88.2% | 0.37+76.2% |
| Total Assets | 389.90+42.3% | 420.58+36.4% | 422.89+23.0% | 232.54+23.3% | 273.91+29.3% | 308.29+33.5% | 343.90+38.3% | 188.66+14.4% |
| Short Term Debt Incl. Current Port. of LT Debt | 2.28-1.3% | 2.23-23.1% | 2.19-26.0% | 2.10-30.5% | 2.31-16.6% | 2.90+28.9% | 2.96+35.2% | 3.02+30.2% |
| Accounts Payable | 3.23-61.7% | 4.36-7.2% | 5.56-13.7% | 3.22-24.1% | 8.43+143.6% | 4.70+86.5% | 6.44+272.3% | 4.24+108.9% |
| Other Current Liabilities | 24.94-2.6% | 21.99-1.2% | 22.53+16.3% | 28.14+22.3% | 25.60+53.9% | 22.25+124.3% | 19.38+86.0% | 23.00+126.4% |
| Total Current Liabilities | 30.45-16.2% | 28.58-4.3% | 30.28+5.2% | 33.47+10.6% | 36.34+59.0% | 29.85+103.2% | 28.78+100.7% | 30.26+108.4% |
| Long Term Debt | 17.34-11.6% | 17.92-11.1% | 18.48-10.6% | 19.06-9.9% | 19.62-10.6% | 20.16-12.5% | 20.66-12.6% | 21.16-11.6% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 47.79-14.6% | 46.51-7.0% | 48.76-1.4% | 52.53+2.2% | 55.97+24.9% | 50.00+32.5% | 49.44+30.2% | 51.42+33.7% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 342.11+57.0% | 374.07+44.8% | 374.13+27.1% | 180.01+31.2% | 217.95+30.5% | 258.29+33.7% | 294.46+39.7% | 137.25+8.5% |
| Total Shareholders Equity | 342.11+57.0% | 374.07+44.8% | 374.13+27.1% | 180.01+31.2% | 217.95+30.5% | 258.29+33.7% | 294.46+39.7% | 137.25+8.5% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 342.11+57.0% | 374.07+44.8% | 374.13+27.1% | 180.01+31.2% | 217.95+30.5% | 258.29+33.7% | 294.46+39.7% | 137.25+8.5% |
| Total Liabilities & Stockholders Equity | 389.90+42.3% | 420.58+36.4% | 422.89+23.0% | 232.54+23.3% | 273.91+29.3% | 308.29+33.5% | 343.90+38.3% | 188.66+14.4% |
| Book Value Per Share per share | 3.07+9.6% | 3.56+6.9% | 3.800.0% | 2.28-32.7% | 2.80-34.7% | 3.33-33.5% | 3.80-31.8% | 3.39-45.3% |
| Tangible Book Value Per Share per share | 3.07+9.6% | 3.56+6.9% | 3.800.0% | 2.28-32.7% | 2.80-34.7% | 3.33-33.5% | 3.80-31.8% | 3.39-45.3% |
| Full-Time Employees people | - | - | - | 121+21.0% | - | - | - | 100+13.6% |
| Price to Book Ratio ratio | 2.28 | 2.63 | 3.16 | 2.02 | 1.85 | 1.28 | 1.09 | 0.93 |
| Return on Assets % | -64.86 | -56.83 | -50.02 | -82.78 | -68.82 | -57.15 | -47.14 | -70.53 |
| Return on Equity % | -76.87 | -65.50 | -57.37 | -109.90 | -86.83 | -68.25 | -55.30 | -94.57 |
| Return on Invested Capital % | -15.01 | -13.98 | -14.45 | -25.01 | -19.27 | -14.18 | -12.47 | -26.89 |
| Quick Ratio ratio | 11.99 | 13.82 | 13.10 | 6.14 | 6.74 | 9.34 | 10.89 | 5.20 |
| Current Ratio ratio | 11.99 | 13.82 | 13.10 | 6.14 | 6.74 | 9.34 | 10.89 | 5.20 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -53.95 | -54.80 | -56.74 | -49.79 | -45.78 | -39.48 | -39.28 | -42.60 |
| Depreciation | 0.42+10.5% | 0.390.0% | 0.40-2.4% | 0.47-4.1% | 0.38-7.3% | 0.39-68.5% | 0.41+24.2% | 0.49-16.9% |
| Other Funds (Non Cash) | 5.16+8.6% | 5.76+36.5% | 6.81+30.2% | 9.01-12.9% | 4.75-17.8% | 4.22+84.3% | 5.23+433.7% | 10.34+1208.9% |
| Funds from Operations | -48.37 | -48.65 | -49.54 | -40.31 | -40.65 | -34.87 | -33.64 | -31.77 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 2.82-60.7% | -3.94 | 2.31+29.1% | -13.25-722.1% | 7.17+152.5% | -2.54-3275.0% | 1.79 | 2.13 |
| Cash from Operating Activities | -45.55 | -52.59 | -47.23 | -53.55 | -33.47 | -37.41 | -31.85 | -29.64 |
| Capital Expenditures | -0.50 | -0.15 | -0.17 | -0.56 | -0.09 | -0.38 | -0.13 | -0.20 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.09+800.0% | 0.00 | 0.00 | 0.00 | 0.01 |
| Purchase or Sale of Investments | -3.26 | -133.44 | 44.92 | 47.58+22.7% | -45.19 | -32.44 | -27.34 | 38.77-14.6% |
| Purchase of Investments | -92.66 | -151.94 | -83.46 | -23.92 | -83.19 | -63.44 | -65.34 | -15.33 |
| Sale Or Maturity of Investments | 89.40+135.3% | 18.50-40.3% | 128.38+237.8% | 71.50+32.2% | 38.00-49.0% | 31.00+102.6% | 38.00-15.6% | 54.10-9.8% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00-100.0% | 0.00 | -0.09 | 0.00 | 0.09 | 0.00-100.0% | -0.01 |
| Cash from Investing Activities | -3.76 | -133.59 | 44.76 | 47.01+21.9% | -45.27 | -32.73 | -27.46 | 38.57-14.9% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 15.88+980.3% | 48.18 | 239.03+25.9% | 5.12+190.9% | 1.47-56.5% | -1.71-131.8% | 189.86+69.4% | 1.76+309.3% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 15.88+980.3% | 48.18 | 239.03+25.9% | 5.12+190.9% | 1.47-56.5% | -1.71-131.8% | 189.86+69.4% | 1.76+309.3% |
| Proceedsfrom Stock Options | 15.74+970.7% | 48.12 | 239.01+25.9% | 194.95 | 1.47-52.6% | -191.54-3673.5% | 189.86+69.6% | -107.11-25009.3% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | -0.20 | -0.24 | -0.14 | -0.14 | -0.13 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | -0.20 | -0.24 | -0.14 | -0.14 | -0.13 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | -0.20 | -0.24 | -0.14 | -0.14 | -0.13 |
| Net Financing Active Other Cash Flow | 0.00-100.0% | 0.29 | 0.00 | 0.23-95.7% | 0.20 | 0.00 | 0.00 | 5.30+7471.4% |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 | 0.00 | 5.11 |
| Cash from Financing Activities | 15.88+1245.8% | 48.47 | 239.03+26.0% | 5.14-25.9% | 1.18-63.8% | -1.60-132.0% | 189.73+76.9% | 6.94+1260.8% |
| Net Change in Cash | -33.42 | -137.71 | 236.56+81.4% | -1.40-108.8% | -77.57 | -71.75 | 130.41+199.4% | 15.86-36.5% |
| Free Cash Flow | -46.04 | -52.74 | -47.40 | -54.12 | -33.56 | -37.79 | -31.98 | -29.85 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 14.61% | 13.3M | 91.1M | 1.17M |
| 2026-10-15 | 14.06% | 12.3M | 87.5M | 1.14M |
| 2026-09-30 | 14.55% | 12.7M | 87.5M | 1.16M |
| 2026-09-15 | 19.55% | 17.1M | 87.5M | 1.53M |
| 2026-08-31 | 18.73% | 16.4M | 87.5M | 1.59M |
| 2026-08-14 | 19.39% | 16.6M | 85.7M | 1.65M |
| 2026-07-31 | 20.00% | 17.0M | 85.2M | 1.71M |
| 2026-07-15 | 22.59% | 17.7M | 78.2M | 1.68M |
| 2026-06-30 | 23.36% | 18.3M | 78.2M | 1.59M |
| 2026-06-15 | 14.85% | 11.6M | 78.2M | 1.14M |
| 2026-05-29 | 12.28% | 9.6M | 78.2M | 1.29M |
| 2026-05-15 | 11.64% | 9.1M | 78.2M | 1.31M |
| 2026-04-30 | 10.38% | 8.8M | 84.9M | 1.31M |
| 2026-04-15 | 12.48% | 9.4M | 75.7M | 1.34M |
| 2026-03-31 | 13.28% | 10.0M | 75.7M | 1.36M |
| 2026-03-13 | 12.89% | 9.8M | 75.7M | 1.29M |
| 2026-02-27 | 15.92% | 9.5M | 59.9M | 1.06M |
| 2026-02-13 | 15.73% | 9.4M | 59.9M | 1.05M |
| 2026-01-30 | 14.84% | 8.7M | 58.3M | 1.08M |
| 2026-01-15 | 14.61% | 8.6M | 58.9M | 1.06M |
Option chain
Expiry 2026-11-20 · underlying 6.91, quoted 13 Nov 07:45 ET · ATM 7.00
Option quotes 12 Nov 12:01 ET. A date on a row is older than the last session (12 Nov). 31 rows.
Implied move 64.40% into expiry (call 2.250 + put 2.200 = 4.450 on 6.91)
Put/call open interest 0.67 (496 puts / 738 calls) · Put/call volume 0.00 (0 puts / 14 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 13 Oct | 1.00 | ITM | 3.90 | 8.50 | 4.90 | 0.00 | - | 3 | 0 | 0 | 0.988 | -0.016 | 0.000 |
| put 1 Jan | OTM | 0.00 | 4.10 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.012 | -0.016 | 0.000 | |
| call 1 Jan | 2.00 | ITM | 2.50 | 7.20 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.980 | -0.016 | 0.000 |
| put 1 Jan | OTM | 0.00 | 4.10 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.020 | -0.016 | 0.000 | |
| call 1 Jan | 3.00 | ITM | 2.10 | 6.50 | 0.00 | 0.00 | 2170.3% +1815.7 | 0 | 0 | 0 | 0.971 | -0.016 | 0.001 |
| put 1 Jan | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 354.7% 0.0 | 0 | 0 | 0 | -0.029 | -0.015 | 0.001 | |
| call 8 Oct | 4.00 | ITM | 0.65 | 5.40 | 2.98 | 0.00 | 1341.0% +1090.1 | 5 | 0 | 0 | 0.959 | -0.015 | 0.001 |
| put 22 Oct | OTM | 0.00 | 0.05 | 0.09 | 0.00 | 0.0% -1238.9 | 50 | 0 | 0 | -0.107 | -0.154 | 0.002 | |
| call 1 Jan | 5.00 | ITM | 0.00 | 4.90 | 0.00 | 0.00 | 1122.2% +949.9 | 0 | 0 | 0 | 0.942 | -0.014 | 0.001 |
| put 1 Jan | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 162.9% 0.0 | 0 | 0 | 0 | -0.063 | -0.013 | 0.001 | |
| call 23 Oct | 6.00 | ITM | 0.00 | 4.90 | 0.70 | 0.00 | 1217.8% -220.2 | 441 | 0 | 0 | 0.875 | -0.199 | 0.002 |
| put 4 Nov | OTM | 0.00 | 4.10 | 0.30 | 0.00 | 1435.8% 0.0 | 423 | 0 | 0 | -0.130 | -0.198 | 0.002 | |
| call 10 Nov | 7.00 | ATM | 0.00 | 4.50 | 0.01 | 0.00 | 1256.2% +17.5 | 6 | 0 | 0 | 0.818 | -0.214 | 0.003 |
| put 2 Oct | ATM | 0.00 | 4.40 | 0.90 | 0.00 | 1221.6% -17.2 | 10 | 0 | 0 | -0.182 | -0.213 | 0.003 | |
| call | 8.00 | OTM | 0.00 | 0.65 | 0.20 | -0.05 | 246.9% 0.0 | 99 | 14 | 14 | 0.426 | -0.064 | 0.004 |
| put 23 Sep | ITM | 0.00 | 4.90 | 1.00 | 0.00 | 1114.6% +867.7 | 13 | 0 | 0 | -0.574 | -0.063 | 0.004 | |
| call 1 Jan | 9.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 310.4% 0.0 | 0 | 0 | 0 | 0.373 | -0.077 | 0.004 |
| put 1 Jan | ITM | 0.00 | 4.90 | 0.00 | 0.00 | 879.0% +568.6 | 0 | 0 | 0 | -0.627 | -0.076 | 0.004 | |
| call 26 Oct | 10.00 | OTM | 0.00 | 0.20 | 0.05 | 0.00 | 176.9% 0.0 | 184 | 0 | 0 | 0.195 | -0.033 | 0.003 |
| put 1 Jan | ITM | 0.50 | 5.20 | 0.00 | 0.00 | 748.7% +521.9 | 0 | 0 | 0 | -0.817 | -0.038 | 0.003 | |
| call 1 Jan | 11.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 263.5% 0.0 | 0 | 0 | 0 | 0.165 | -0.043 | 0.003 |
| put 1 Jan | ITM | 1.50 | 5.90 | 0.00 | 0.00 | 719.2% +455.8 | 0 | 0 | 0 | -0.835 | -0.042 | 0.003 | |
| call 1 Jan | 12.00 | OTM | 0.00 | 1.50 | 0.00 | 0.00 | 295.4% 0.0 | 0 | 0 | 0 | 0.152 | -0.046 | 0.002 |
| put 1 Jan | ITM | 2.50 | 7.00 | 0.00 | 0.00 | 782.9% +487.6 | 0 | 0 | 0 | -0.848 | -0.044 | 0.002 | |
| call 1 Jan | 13.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 323.5% 0.0 | 0 | 0 | 0 | 0.143 | -0.048 | 0.002 |
| put 1 Jan | ITM | 3.50 | 8.00 | 0.00 | 0.00 | 817.5% +494.1 | 0 | 0 | 0 | -0.857 | -0.046 | 0.002 | |
| call 1 Jan | 14.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 348.8% 0.0 | 0 | 0 | 0 | 0.136 | -0.050 | 0.002 |
| put 1 Jan | ITM | 4.50 | 9.00 | 0.00 | 0.00 | 848.5% +499.8 | 0 | 0 | 0 | -0.864 | -0.048 | 0.002 | |
| call 1 Jan | 15.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 371.7% 0.0 | 0 | 0 | 0 | 0.130 | -0.052 | 0.002 |
| put 1 Jan | ITM | 5.50 | 10.00 | 0.00 | 0.00 | 876.4% +504.9 | 0 | 0 | 0 | -0.870 | -0.050 | 0.002 | |
| call 1 Jan | 16.00 | OTM | 0.00 | 4.10 | 0.00 | 0.00 | 392.6% 0.0 | 0 | 0 | 0 | 0.125 | -0.053 | 0.002 |
| put 1 Jan | ITM | 6.50 | 11.00 | 0.00 | 0.00 | 902.1% +509.6 | 0 | 0 | 0 | -0.875 | -0.051 | 0.002 |
Latest SEC filings
30 of 738AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-11-04, period ended 2026-09-30. 10-K filed 2026-03-19, period ended 2025-12-31. SLDB on EDGAR
page 1 of 25Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-06 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000255 index |
| 2026-11-04 | 10-Q | All annual, quarterly, and current reports | 2026-09-30 | 0001193125-26-447178 index |
| 2026-10-26 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-01 · transaction | 0001193125-26-431910 index |
| 2026-10-20 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-18 · transaction | 0001193125-26-426668 index |
| 2026-10-06 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-10-02 · transaction | 0001193125-26-415649 index |
| 2026-08-14 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001193125-26-352656 index |
| 2026-08-14 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0000902664-26-003502 index |
| 2026-08-06 | 8-K | All annual, quarterly, and current reports | 2026-08-06 | 0001193125-26-338438 index |
| 2026-08-06 | 424B5 | Registration statements and prospectuses | no report period | 0001193125-26-338410 index |
| 2026-08-06 | S-3ASR | Registration statements and prospectuses | no report period | 0001193125-26-338387 index |
| 2026-08-06 | 10-Q | All annual, quarterly, and current reports | 2026-06-30 | 0001193125-26-337935 index |
| 2026-08-06 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0000315066-26-002128 index |
| 2026-07-30 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0002012383-26-003093 index |
| 2026-07-07 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-07-02 · transaction | 0001193125-26-297456 index |
| 2026-06-24 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000183 index |
| 2026-06-24 | 3 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-22 | 0001231919-26-000697 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267504 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267503 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267502 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267501 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267500 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267499 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267496 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267494 index |
| 2026-06-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-10 · transaction | 0001193125-26-267489 index |
| 2026-06-10 | 8-K | All annual, quarterly, and current reports | 2026-06-10 | 0001193125-26-265804 index |
| 2026-06-05 | 424B7 | Registration statements and prospectuses | no report period | 0001193125-26-259503 index |
| 2026-05-12 | 10-Q | All annual, quarterly, and current reports | 2026-03-31 | 0001193125-26-219337 index |
| 2026-05-05 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0002005369-26-000031 index |
| 2026-04-27 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0002012383-26-001720 index |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 24.58K | 1 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 2.50M | 19 |
| 2026-01 | 0 | 0 | 37.04K | 3 |
| 2025-12 | 0 | 0 | 117.14K | 4 |
| 2025-11 | 0 | 0 | 13.51K | 1 |
Institutional holders
| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12.23% |
| PERCEPTIVE ADVISORS LLC | 12.09% |
| Bain Capital Life Sciences Investors, LLC | 9.96% |
| Siren, L.L.C. | 7.17% |
| BlackRock, Inc. | 7.04% |
| FMR LLC | 6.78% |
| ARMISTICE CAPITAL, LLC | 4.35% |
| Jupiter Topco LLC | 4.11% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.07% |
| RTW INVESTMENTS, LP | 3.95% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.20% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.62% |
| Select Biotechnology Portfolio | 2.43% |
| iShares Russell 2000 ETF | 2.09% |
| Columbia Small Cap Growth Fund | 1.64% |
| Franklin Biotechnology Discovery Fund | 1.43% |
| Fidelity Small Cap Index Fund | 0.88% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.79% |
| Fidelity Advisor Biotechnology Fund | 0.69% |
| iShares Biotechnology ETF | 0.56% |
OakChart. SLDB. Cached 15 minutes. Terms